📣 This morning, @GMA reported on a “a new device just cleared by the FDA that could be a game-changer for the 300,000 Americans with spinal cord injury.” 📺 That device is ARC-EX. @ABC correspondent Will Reeve, son of Christopher Reeve, called ARC-EX a “breakthrough for people living with spinal cord injury,” and invoked his deep ties to the spinal cord injury (SCI) community by providing context on this historic event. ⭐️ “Progress in spinal cord injury research is usually measured in decades,” said Reeve, “so this is a long time coming. And to be able to say this is here and getting out to people who need it is a big moment.” Will interviewed Up-LIFT trial principal investigator and University of Washington professor and neuroscientist Dr. Chet Moritz about our technology. The story centered around trial participant Jessie Owen aka @itswheelyjess, whose life transformed in every way from this therapy. 🙏 Thank you, GMA and ABC News for shining a light on the longstanding unmet needs of the SCI Community and showing how a device like ARC-EX can, in Will’s words, offer “a new level of freedom and hope.” As Jessie told Will – “The future of spinal cord injury treatment is being written right now. This is the moment. And this provides the hope and the stepping stone to start that journey.” ✨ #EmpoweringMovement #SCI #GMA #Hope #Freedom Note: The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive). Please note that all other ONWARD Medical devices and therapies, including ARC-IM®, ARC-BCI®, and ARC Therapy™ with brain-computer interfaces (BCIs), are investigational and not commercially approved. Patient testimonials reflect individual experiences and outcomes, which may vary. Please review the full product label and clinical study data.  goodmorningamerica.com/welln…